Clinical Trials Directory

Trials / Terminated

TerminatedNCT02240381

Predicting Development of Diabetes Mellitus in Patients Undergoing Allogeneic Stem Cell Transplant

Metabolic and CD4+ T Cell Dysregulation in Post-Transplant Diabetes Mellitus

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
22 (actual)
Sponsor
Vanderbilt-Ingram Cancer Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This clinical trial studies the physiology and immunology of new-onset post-transplant diabetes mellitus in patients undergoing allogeneic stem cell transplantation. Oral glucose tolerance testing (OGTT), euglycemic hyperinsulinemic clamps, and immune assays will be used to define the mechanisms associated with abnormal glucose homeostasis following stem cell transplantation. Information from this clinical trial could be used to develop standardized screening procedures or to develop optimal treatment strategies for patients developing post-transplant diabetes mellitus.

Detailed description

PRIMARY OBJECTIVES: I. To determine whether pre-transplant insulin resistance predicts for the development of new onset post-transplant diabetes mellitus (PTDM) in individuals without diabetes undergoing matched related donor (MRD) hematopoietic stem cell transplant (HCT). II. To define the role of circulating tissue-specific Th1 cells in the development of PTDM. III. To characterize the phenotype and function of circulating tissue-specific regulatory T cells (Tregs) in HCT recipients with or without PTDM. OUTLINE: Patients undergo OGTT and a standard 2-step euglycemic hyperinsulinemic clamp procedure prior to HCT. Patients then undergo repeat OGTT and a 2-step euglycemic hyperinsulinemic clamp procedure once after HCT between days 90-100.

Conditions

Interventions

TypeNameDescription
PROCEDUREassessment of therapy complicationsDuring OGTT 75gm of glucose will be given followed by phlebotomy
PROCEDUREassessment of therapy complicationsDuring clamp procedure tritiated glucose, D20, regular insulin will be given, followed by phlebotomy.
OTHERlaboratory biomarker analysisCorrelative studies

Timeline

Start date
2014-11-20
Primary completion
2019-01-08
Completion
2019-01-08
First posted
2014-09-15
Last updated
2019-07-18

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02240381. Inclusion in this directory is not an endorsement.